Bioreactor productivity and media cost comparison for different intensified cell culture processes
暂无分享,去创建一个
Sen Xu | Rubin Jiang | Hao Chen | John Gavin | Sen Xu | Rubin Jiang | Hao Chen | J. Gavin
[1] Gerhard Schembecker,et al. Cost evaluation of antibody production processes in different operation modes , 2016 .
[2] H. Eisen,et al. The secretion of antibody by isolated lymph node cells. , 1961, The Journal of biological chemistry.
[3] Paul W. Sauer,et al. A high-yielding, generic fed-batch cell culture process for production of recombinant antibodies. , 2000, Biotechnology and bioengineering.
[4] S. Chamow,et al. Therapeutic antibody expression technology. , 2001, Current opinion in biotechnology.
[5] Brian Kelley,et al. Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations , 2007, Biotechnology progress.
[6] Marco Jenzsch,et al. Optimizing capacity utilization by large scale 3000 L perfusion in seed train bioreactors , 2013, Biotechnology progress.
[7] Mohamed Al-Rubeai,et al. Animal Cell Culture , 2015, Cell Engineering.
[8] Suzanne S Farid,et al. Process economics of industrial monoclonal antibody manufacture. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[9] Yao-ming Huang,et al. Perfusion seed cultures improve biopharmaceutical fed‐batch production capacity and product quality , 2014, Biotechnology progress.
[10] Ye Zhang,et al. Very High Density of CHO Cells in Perfusion by ATF or TFF in WAVE Bioreactor™. Part I. Effect of the Cell Density on the Process , 2013, Biotechnology progress.
[11] H. Dosch,et al. Limiting dilution analysis of the B cell compartment in human bone marrow , 1986, European journal of immunology.
[12] Brian Kelley,et al. Industrialization of mAb production technology: The bioprocessing industry at a crossroads , 2009, mAbs.
[13] Florian M Wurm,et al. Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[14] Jochen Strube,et al. Challenges in biotechnology production—generic processes and process optimization for monoclonal antibodies , 2005 .
[15] Rashmi Kshirsagar,et al. Concentrated fed-batch cell culture increases manufacturing capacity without additional volumetric capacity. , 2016, Journal of biotechnology.
[16] Ningning Ma,et al. A single nutrient feed supports both chemically defined NS0 and CHO fed‐batch processes: Improved productivity and lactate metabolism , 2009, Biotechnology progress.
[17] Konstantin B Konstantinov,et al. The future of industrial bioprocessing: batch or continuous? , 2015, Biotechnology and bioengineering.
[18] M. Care,et al. In Vitro Generation of Long-lived Human Plasma Cells , 2012, The Journal of Immunology.
[19] B. Kelley,et al. An improved manufacturing process for Xyntha/ReFacto AF , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[20] Gerhard Schembecker,et al. Developing the biofacility of the future based on continuous processing and single-use technology. , 2015, Journal of biotechnology.
[21] C. Hoy,et al. Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activator. , 2000, Biotechnology and bioengineering.
[22] Suzanne S Farid,et al. Fed‐batch and perfusion culture processes: Economic, environmental, and operational feasibility under uncertainty , 2013, Biotechnology and bioengineering.
[23] Paola Lettieri,et al. Life‐cycle and cost of goods assessment of fed‐batch and perfusion‐based manufacturing processes for mAbs , 2016, Biotechnology progress.
[24] R. Werner,et al. Economic aspects of commercial manufacture of biopharmaceuticals. , 2004, Journal of biotechnology.
[25] Charles L. Cooney,et al. White Paper on Continuous Bioprocessing , 2014 .
[26] Suzanne S Farid,et al. Established bioprocesses for producing antibodies as a basis for future planning. , 2006, Advances in biochemical engineering/biotechnology.
[27] Sen Xu,et al. High-density mammalian cell cultures in stirred-tank bioreactor without external pH control. , 2016, Journal of biotechnology.
[28] M. Fussenegger,et al. Molecular engineering of exocytic vesicle traffic enhances the productivity of Chinese hamster ovary cells , 2009, Biotechnology and bioengineering.
[29] Konstantin B Konstantinov,et al. White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. , 2015, Journal of pharmaceutical sciences.
[30] Sen Xu,et al. Improving lactate metabolism in an intensified CHO culture process: productivity and product quality considerations , 2016, Bioprocess and Biosystems Engineering.
[31] T. Bibila,et al. In Pursuit of the Optimal Fed‐Batch Process for Monoclonal Antibody Production , 1995, Biotechnology progress.
[32] Jason Walther,et al. Delivering Steady-State Product Quality with An Intensified And Integrated Perfusion Cell Culture Process , 2015 .
[33] Daniel Cummings,et al. Integrated continuous production of recombinant therapeutic proteins , 2012, Biotechnology and bioengineering.
[34] Nimish Dalal,et al. Cell culture process operations for recombinant protein production. , 2014, Advances in biochemical engineering/biotechnology.
[35] Yashas Rajendra,et al. Generation of stable Chinese hamster ovary pools yielding antibody titers of up to 7.6 g/L using the piggyBac transposon system , 2016, Biotechnology progress.
[36] R. Ahmed,et al. Humoral immunity due to long-lived plasma cells. , 1998, Immunity.
[37] Mohamed Al-Rubeai,et al. Bioreactor Systems for Producing Antibody from Mammalian Cells , 2011 .
[38] Huong Nguyen,et al. A new large‐scale manufacturing platform for complex biopharmaceuticals , 2012, Biotechnology and bioengineering.
[39] Sevim Duvar,et al. Developing an upstream process for a monoclonal antibody including medium optimization , 2013, BMC Proceedings.
[40] Jason Walther,et al. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. , 2015, Journal of biotechnology.
[41] Michele M. Myers,et al. Addressing Changes Associated with Technology Transfer: A Case Study , 2010 .
[42] Alex Xenopoulos,et al. A new, integrated, continuous purification process template for monoclonal antibodies: Process modeling and cost of goods studies. , 2015, Journal of biotechnology.
[43] Thomas Ryll,et al. Maximizing productivity of CHO cell‐based fed‐batch culture using chemically defined media conditions and typical manufacturing equipment , 2010, Biotechnology progress.
[44] Marcella Yu,et al. Effects of cell culture conditions on antibody N‐linked glycosylation—what affects high mannose 5 glycoform , 2011, Biotechnology and bioengineering.